Literature DB >> 19950108

COMU: a third generation of uronium-type coupling reagents.

Ayman El-Faham1, Fernando Albericio.   

Abstract

COMU is a third generation of uronium-type coupling reagent based on ethyl 2-cyano-2-(hydroxyimino)acetate (Oxyma) as well as a morpholino carbon skeleton. The presence of the morpholino group has a marked influence on the solubility, stability and reactivity of the reagent. COMU performed extremely well in the presence of only 1 equiv. of base, thereby confirming the effect of the hydrogen bond acceptor in the reaction. The by-products of COMU are water soluble and easily removed, making it an excellent choice of coupling reagent for solution-phase peptide synthesis. Finally, COMU shows a less hazardous safety profile than benzotriazole-based reagents, such as HATU and HBTU, which in addition exhibit unpredictable autocatalytic decompositions and therefore a higher risk of explosion. Furthermore, in contrast to benzotriazole-based reagents, COMU is significantly less likely to cause allergic reaction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19950108     DOI: 10.1002/psc.1204

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  15 in total

1.  Target Identification and Mechanism of Action of Picolinamide and Benzamide Chemotypes with Antifungal Properties.

Authors:  Verena Pries; Christina Nöcker; Danish Khan; Philipp Johnen; Zebin Hong; Ashutosh Tripathi; Anna-Lena Keller; Michael Fitz; Francesca Perruccio; Ireos Filipuzzi; Sasikala Thavam; Thomas Aust; Ralph Riedl; Slava Ziegler; Fulvia Bono; Gabriel Schaaf; Vytas A Bankaitis; Herbert Waldmann; Dominic Hoepfner
Journal:  Cell Chem Biol       Date:  2018-01-04       Impact factor: 8.116

2.  Improving the Fmoc Solid Phase Synthesis of the Cyclic Hexapeptide Complement C5a Antagonist, PMX205.

Authors:  R C Delisle Milton; S C Milton; A R Chamberlin
Journal:  Int J Pept Res Ther       Date:  2011-12       Impact factor: 1.931

Review 3.  Marine Cyclic Peptides: Antimicrobial Activity and Synthetic Strategies.

Authors:  Ricardo Ribeiro; Eugénia Pinto; Carla Fernandes; Emília Sousa
Journal:  Mar Drugs       Date:  2022-06-15       Impact factor: 6.085

4.  Synthesis of cruentaren A.

Authors:  Bhaskar Reddy Kusuma; Gary E L Brandt; Brian S J Blagg
Journal:  Org Lett       Date:  2012-12-03       Impact factor: 6.005

5.  Linker design for the modular assembly of multifunctional and targeted platinum(ii)-containing anticancer agents.

Authors:  S Ding; U Bierbach
Journal:  Dalton Trans       Date:  2016-08-16       Impact factor: 4.390

6.  A new quinoxaline-containing peptide induces apoptosis in cancer cells by autophagy modulation.

Authors:  Rubí Zamudio-Vázquez; Saška Ivanova; Miguel Moreno; Maria Isabel Hernandez-Alvarez; Ernest Giralt; Axel Bidon-Chanal; Antonio Zorzano; Fernando Albericio; Judit Tulla-Puche
Journal:  Chem Sci       Date:  2015-05-20       Impact factor: 9.825

7.  Low-cost synthesis of peptide libraries and their use for binding studies via temperature-related intensity change.

Authors:  Clemens Schulte; Vladimir Khayenko; Amit Jean Gupta; Hans Michael Maric
Journal:  STAR Protoc       Date:  2021-06-15

8.  Synthesis of N-peptide-6-amino-D-luciferin Conjugates.

Authors:  Anita K Kovács; Péter Hegyes; Gábor J Szebeni; Lajos I Nagy; László G Puskás; Gábor K Tóth
Journal:  Front Chem       Date:  2018-04-19       Impact factor: 5.221

9.  Oxime-based carbonates as useful reagents for both N-protection and peptide coupling.

Authors:  Yahya El-Sayed Jad; Sherine N Khattab; Ayman El-Faham; Fernando Albericio
Journal:  Molecules       Date:  2012-12-05       Impact factor: 4.411

10.  PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties.

Authors:  Piotr Garnuszek; Urszula Karczmarczyk; Michał Maurin; Arkadiusz Sikora; Jolanta Zaborniak; Justyna Pijarowska-Kruszyna; Antoni Jaroń; Monika Wyczółkowska; Wioletta Wojdowska; Dariusz Pawlak; Piotr F J Lipiński; Renata Mikołajczak
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.